COR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cencora Inc (COR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong financial performance, positive analyst sentiment, and strategic acquisitions that align with long-term growth. Despite recent price declines, the fundamentals and catalysts suggest a favorable entry point for long-term investors.
The stock is currently trading below its pivot level of 334.434, with support at 319.388 and resistance at 349.48. The MACD is negative (-3.186) but contracting, indicating potential stabilization. RSI is at 25.365, suggesting the stock is nearing oversold territory. Moving averages are converging, which may indicate a potential reversal in trend.
Hedge funds are significantly increasing their holdings, with a 2472.49% increase in buying activity last quarter.
Positive analyst sentiment with multiple upgrades and increased price targets, including a high target of $
Recent acquisition of EyeSouth Partners' retina business for $1.1 billion, expected to boost EPS in the next 12 months.
Strong Q1 2026 financial performance with revenue, net income, EPS, and gross margin showing double-digit growth.
Recent price decline of -2.17% in the regular market and -0.72% post-market.
MACD and RSI indicators suggest short-term bearish momentum.
No recent congress trading data or AI trading signals to support immediate action.
Cencora reported strong Q1 2026 financials with a 5.45% YoY increase in revenue to $85.93 billion, a 14.54% YoY increase in net income to $559.65 million, and a 14.80% YoY increase in EPS to 2.87. Gross margin also improved by 17.63% YoY to 3.27%, reflecting robust operational efficiency.
Analyst sentiment is highly positive, with multiple upgrades and increased price targets. Recent ratings include a $440 price target from Jefferies, a $429 target from Wells Fargo, and a $425 target from Barclays. Analysts highlight the company's leadership in specialty healthcare, strategic acquisitions, and cleared regulatory risks as key drivers for growth.
